Scientific specifications of medicinal products subject to joint clinical assessments
This document is intended to clarify the scientific specifications of ‘new active substance’ and ‘therapeutic indication of treatment of cancer’ to determine if a medicinal product shall be subject to Joint Clinical Assessment between 12 January 2025 and 13 January 2030.
Read the publication by EC Directorate-General for Health and Food Safety on 13 June 2024.
OpenEdition vous propose de citer ce billet de la manière suivante :
lsgilbert (8 juillet 2024). Scientific specifications of medicinal products subject to joint clinical assessments. ELSIBI. Consulté le 19 février 2026 à l’adresse https://doi.org/10.58079/11yms





